Wellington Management, an investment firm, led a $150m funding round in Saluda Medical, a global medical device company, with participation from Fidelity Management & Research Company, TPG, Redmile Group, Action Potential Venture Capital and T. Rowe Price Associates. "We are very excited to add two elite healthcare investors to our shareholder base while existing investors continue to support our mission to transform patients' lives with neural sensing technology and revolutionize the field of neuromodulation. With this financing, which follows the recent presentation of our 36-month data, the decision by CMS to grant Evoke TPT payment, and our initial limited commercial release, we are more prepared than ever to fundamentally transform the neuromodulation space with our clinically proven, technologically unrivaled platform," Jim Schuermann, Saluda Medical President and CEO.